UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Primary focal hyperhidrosis

Authors
C Christopher Smith, MD
David Pariser, MD
Section Editors
Robert P Dellavalle, MD, PhD, MSPH
Mark V Dahl, MD
Deputy Editor
Abena O Ofori, MD

INTRODUCTION

Hyperhidrosis (excessive sweating) is a common condition rarely due to significant underlying pathology that may have serious social, emotional, and professional consequences.

The diagnosis and treatment of primary focal hyperhidrosis is reviewed here. Night sweats and menopausal hot flashes are discussed separately. (See "Approach to the patient with night sweats" and "Menopausal hot flashes".)

DEFINITION

Hyperhidrosis is the secretion of sweat in amounts greater than physiologically needed for thermoregulation. It is most commonly a chronic idiopathic (primary) condition; however, secondary medical conditions or medications should be excluded. Idiopathic hyperhidrosis localized to certain areas of the body is called primary focal hyperhidrosis. Primary focal hyperhidrosis usually affects the axillae, palms, and soles. The condition may also affect other sites, such as the face, scalp, inguinal, and inframammary areas.

A consensus panel suggested the following diagnostic criteria for primary focal hyperhidrosis [1]:

Focal, visible, excessive sweating of at least six months duration without apparent cause

                                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Dec 30 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004; 51:274.
  2. Moran KT, Brady MP. Surgical management of primary hyperhidrosis. Br J Surg 1991; 78:279.
  3. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004; 51:241.
  4. Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol 2009; 61:242.
  5. Adar R, Kurchin A, Zweig A, Mozes M. Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg 1977; 186:34.
  6. Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol 1999; 38:561.
  7. Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg 2002; 35:382.
  8. Scrivener Y, Cribier B. [Morphology of sweat glands]. Morphologie 2002; 86:5.
  9. Lonsdale-Eccles A, Leonard N, Lawrence C. Axillary hyperhidrosis: eccrine or apocrine? Clin Exp Dermatol 2003; 28:2.
  10. Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. I. Normal sweat gland function. J Am Acad Dermatol 1989; 20:537.
  11. Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. II. Disorders of sweat gland function. J Am Acad Dermatol 1989; 20:713.
  12. Van den Brande P, Vijgen J, Demedts M. Clinical spectrum of pulmonary tuberculosis in older patients: comparison with younger patients. J Gerontol 1991; 46:M204.
  13. Bollinger RC, Brookmeyer RS, Mehendale SM, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA 1997; 278:2085.
  14. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.
  15. Gobbi PG, Pieresca C, Ricciardi L, et al. Night sweats in Hodgkin's disease. A manifestation of preceding minor febrile pulses. Cancer 1990; 65:2074.
  16. Spaulding SW, Lippes H. Hyperthyroidism. Causes, clinical features, and diagnosis. Med Clin North Am 1985; 69:937.
  17. Vinik AI, McLeod MK, Fig LM, et al. Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 1989; 18:865.
  18. Trop CS, Bennett CJ. The evaluation of autonomic dysreflexia. Semin Urol 1992; 10:95.
  19. Matarasso SL. Treatment of facial chromhidrosis with botulinum toxin type A. J Am Acad Dermatol 2005; 52:89.
  20. Wang A, Wysong A, Nord KM, et al. Chromhidrosis: a rare diagnosis requiring clinicopathologic correlation. Am J Dermatopathol 2014; 36:853.
  21. Polat M, Dikilitaş M, Gözübüyükoğullari A, Alli N. Apocrine chromhidrosis. Clin Exp Dermatol 2009; 34:e373.
  22. Beer K, Oakley H. Axillary chromhidrosis: report of a case, review of the literature and treatment considerations. J Cosmet Dermatol 2010; 9:318.
  23. Pérez Tato B, Zamora Martínez E, Sánchez Albisua B, et al. Facial and axillary apocrine chromhidrosis. Dermatol Online J 2012; 18:13.
  24. Wu JM, Mamelak AJ, Nussbaum R, McElgunn PS. Botulinum toxin a in the treatment of chromhidrosis. Dermatol Surg 2005; 31:963.
  25. Marks JG Jr. Treatment of apocrine chromhidrosis with topical capsaicin. J Am Acad Dermatol 1989; 21:418.
  26. Gandhi V, Vij A, Bhattacharya SN. Apocrine chromhidrosis localized to the areola in an Indian female treated with topical capsaicin. Indian J Dermatol Venereol Leprol 2006; 72:382.
  27. Saff DM, Owens R, Kahn TA. Apocrine chromhidrosis involving the areolae in a 15-year-old amateur figure skater. Pediatr Dermatol 1995; 12:48.
  28. Harada K, Morohoshi T, Ikeda T, Shimada S. A patient with pseudochromhidrosis presenting with pink nails. J Am Acad Dermatol 2012; 67:e74.
  29. Rodríguez-Martín M, Rodríguez MS, Cabrera AN. Palmar and digital black pseudochromhidrosis: a case report. Int J Dermatol 2010; 49:562.
  30. Allegue F, Hermo JA, Fachal C, Alfonsín N. Localized green pigmentation in a patient with hyperbilirubinemia. J Am Acad Dermatol 1996; 35:108.
  31. Garcia SF, Egbert B, Swetter SM. Hereditary ochronosis: hyperpigmented skin overlying cartilaginous structures. Cutis 1999; 63:337.
  32. Wang Z, Yu Z, Su J, et al. A case of hematidrosis successfully treated with propranolol. Am J Clin Dermatol 2010; 11:440.
  33. Mora E, Lucas J. Hematidrosis: blood sweat. Blood 2013; 121:1493.
  34. Carvalho AC, Machado-Pinto J, Nogueira GC, et al. Hematidrosis: a case report and review of the literature. Int J Dermatol 2008; 47:1058.
  35. Manonukul J, Wisuthsarewong W, Chantorn R, et al. Hematidrosis: a pathologic process or stigmata. A case report with comprehensive histopathologic and immunoperoxidase studies. Am J Dermatopathol 2008; 30:135.
  36. Praveen BK, Vincent J. Hematidrosis and hemolacria: a case report. Indian J Pediatr 2012; 79:109.
  37. Scholes KT, Crow KD, Ellis JP, et al. Axillary hyperhidrosis treated with alcoholic solution of aluminium chloride hexahydrate. Br Med J 1978; 2:84.
  38. Goh CL. Aluminum chloride hexahydrate versus palmar hyperhidrosis. Evaporimeter assessment. Int J Dermatol 1990; 29:368.
  39. Pariser DM, Ballard A. Topical therapies in hyperhidrosis care. Dermatol Clin 2014; 32:485.
  40. Stolman LP. Treatment of hyperhidrosis. Dermatol Clin 1998; 16:863.
  41. de Almeida AR, Montagner S. Botulinum toxin for axillary hyperhidrosis. Dermatol Clin 2014; 32:495.
  42. Heckmann M, Ceballos-Baumann AO, Plewig G, Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001; 344:488.
  43. Naumann M, Lowe NJ, Kumar CR, et al. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003; 139:731.
  44. Schnider P, Moraru E, Kittler H, et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol 2001; 145:289.
  45. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001; 323:596.
  46. Wollina U, Karamfilov T, Konrad H. High-dose botulinum toxin type A therapy for axillary hyperhidrosis markedly prolongs the relapse-free interval. J Am Acad Dermatol 2002; 46:536.
  47. Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox. Dermatol Surg 1998; 24:817.
  48. Naumann M, Hofmann U, Bergmann I, et al. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998; 134:301.
  49. Heckmann M, Plewig G, Hyperhidrosis Study Group. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 2005; 141:1255.
  50. Lecouflet M, Leux C, Fenot M, et al. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients. J Am Acad Dermatol 2013; 69:960.
  51. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004; 19 Suppl 8:S92.
  52. Dressler D, Wohlfahrt K, Meyer-Rogge E, et al. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 2010; 36 Suppl 4:2182.
  53. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25:2211.
  54. Kontochristopoulos G, Gregoriou S, Zakopoulou N, Rigopoulos D. Cryoanalgesia with dichlorotetrafluoroethane spray versus ice packs in patients treated with botulinum toxin-a for palmar hyperhidrosis: Self-controlled study. Dermatol Surg 2006; 32:873.
  55. Richards RN. Ethyl chloride spray for sensory relief for botulinum toxin injections of the hands and feet. J Cutan Med Surg 2009; 13:253.
  56. Smith KC, Comite SL, Storwick GS. Ice minimizes discomfort associated with injection of botulinum toxin type A for the treatment of palmar and plantar hyperhidrosis. Dermatol Surg 2007; 33:S88.
  57. O'Riordan JM, Fitzgerald E, Gowing C, et al. Topical local anaesthetic (tetracaine) reduces pain from botulinum toxin injections for axillary hyperhidrosis. Br J Surg 2006; 93:713.
  58. Smith KC, Comite SL, Balasubramanian S, et al. Vibration anesthesia: a noninvasive method of reducing discomfort prior to dermatologic procedures. Dermatol Online J 2004; 10:1.
  59. Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg 2012; 38:728.
  60. Johnson JE, O'Shaughnessy KF, Kim S. Microwave thermolysis of sweat glands. Lasers Surg Med 2012; 44:20.
  61. Glaser DA, Coleman WP 3rd, Fan LK, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 2012; 38:185.
  62. Lee SJ, Chang KY, Suh DH, et al. The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study. J Cosmet Laser Ther 2013; 15:255.
  63. Lupin M, Hong HC, OʼShaughnessy KF. Long-term efficacy and quality of life assessment for treatment of axillary hyperhidrosis with a microwave device. Dermatol Surg 2014; 40:805.
  64. Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. Dermatol Clin 2014; 32:533.
  65. Suh DH, Lee SJ, Kim K, Ryu HJ. Transient median and ulnar neuropathy associated with a microwave device for treating axillary hyperhidrosis. Dermatol Surg 2014; 40:482.
  66. Pariser DM. Incorporating diagnosis and treatment of hyperhidrosis into clinical practice. Dermatol Clin 2014; 32:565.
  67. Keaveny TV, Fitzgerald PA, Donnelly C, Shanik GD. Surgical management of hyperhidrosis. Br J Surg 1977; 64:570.
  68. Bechara FG, Gambichler T, Bader A, et al. Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage. J Am Acad Dermatol 2007; 57:207.
  69. Swinehart JM. Treatment of axillary hyperhidrosis: combination of the starch-iodine test with the tumescent liposuction technique. Dermatol Surg 2000; 26:392.
  70. Bechara FG, Sand M, Sand D, et al. Surgical treatment of axillary hyperhidrosis: a study comparing liposuction cannulas with a suction-curettage cannula. Ann Plast Surg 2006; 56:654.
  71. Boni R. Tumescent suction curettage in the treatment of axillary hyperhidrosis: experience in 63 patients. Dermatology 2006; 213:215.
  72. Wollina U, Köstler E, Schönlebe J, Haroske G. Tumescent suction curettage versus minimal skin resection with subcutaneous curettage of sweat glands in axillary hyperhidrosis. Dermatol Surg 2008; 34:709.
  73. Darabaneanu S, Darabaneanu HA, Niederberger U, et al. Long-term efficacy of subcutaneous sweat gland suction curettage for axillary hyperhidrosis: a prospective gravimetrically controlled study. Dermatol Surg 2008; 34:1170.
  74. Ibrahim O, Kakar R, Bolotin D, et al. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol 2013; 69:88.
  75. Proebstle TM, Schneiders V, Knop J. Gravimetrically controlled efficacy of subcorial curettage: a prospective study for treatment of axillary hyperhidrosis. Dermatol Surg 2002; 28:1022.
  76. Feldmeyer L, Bogdan I, Moser A, et al. Short- and long-term efficacy and mechanism of action of tumescent suction curettage for axillary hyperhidrosis. J Eur Acad Dermatol Venereol 2015; 29:1933.
  77. Field LM. Re: Insufficient aggressiveness with tumescent suction curettage. Dermatol Surg 2009; 35:555.
  78. Tupker RA, Harmsze AM, Deneer VH. Oxybutynin therapy for generalized hyperhidrosis. Arch Dermatol 2006; 142:1065.
  79. Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. Br J Dermatol 2007; 157:118.
  80. Walling HW. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol 2012; 66:387.
  81. Wolosker N, de Campos JR, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg 2012; 55:1696.
  82. Schollhammer M, Brenaut E, Menard-Andivot N, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. Br J Dermatol 2015; 173:1163.
  83. Lee HH, Kim DW, Kim DW, Kim C. Efficacy of glycopyrrolate in primary hyperhidrosis patients. Korean J Pain 2012; 25:28.
  84. Paller AS, Shah PR, Silverio AM, et al. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol 2012; 67:918.
  85. Glaser DA. Oral medications. Dermatol Clin 2014; 32:527.
  86. Wolosker N, de Campos JR, Kauffman P, et al. The use of oxybutynin for treating axillary hyperhidrosis. Ann Vasc Surg 2011; 25:1057.
  87. Wolosker N, Campos JR, Kauffman P, et al. The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol 2011; 86:451.
  88. Wolosker N, de Campos JR, Kauffman P, et al. An alternative to treat palmar hyperhidrosis: use of oxybutynin. Clin Auton Res 2011; 21:389.
  89. Kuritzky A, Hering R, Goldhammer G, Bechar M. Clonidine treatment in paroxysmal localized hyperhidrosis. Arch Neurol 1984; 41:1210.
  90. Torch EM. Remission of facial and scalp hyperhidrosis with clonidine hydrochloride and topical aluminum chloride. South Med J 2000; 93:68.
  91. Mack GW, Shannon LM, Nadel ER. Influence of beta-adrenergic blockade on the control of sweating in humans. J Appl Physiol (1985) 1986; 61:1701.
  92. Quraishy MS, Giddings AE. Treating hyperhidrosis. BMJ 1993; 306:1221.
  93. Reinauer S, Neusser A, Schauf G, Hölzle E. Iontophoresis with alternating current and direct current offset (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosis. Br J Dermatol 1993; 129:166.
  94. Drott C, Göthberg G, Claes G. Endoscopic transthoracic sympathectomy: an efficient and safe method for the treatment of hyperhidrosis. J Am Acad Dermatol 1995; 33:78.
  95. Gossot D, Galetta D, Pascal A, et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thorac Surg 2003; 75:1075.
  96. Herbst F, Plas EG, Függer R, Fritsch A. Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limbs. A critical analysis and long-term results of 480 operations. Ann Surg 1994; 220:86.
  97. Dumont P, Denoyer A, Robin P. Long-term results of thoracoscopic sympathectomy for hyperhidrosis. Ann Thorac Surg 2004; 78:1801.
  98. Atkinson JL, Fode-Thomas NC, Fealey RD, et al. Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin Proc 2011; 86:721.
  99. Licht PB, Pilegaard HK. Severity of compensatory sweating after thoracoscopic sympathectomy. Ann Thorac Surg 2004; 78:427.
  100. Neumayer C, Zacherl J, Holak G, et al. Limited endoscopic thoracic sympathetic block for hyperhidrosis of the upper limb: reduction of compensatory sweating by clipping T4. Surg Endosc 2004; 18:152.
  101. Sugimura H, Spratt EH, Compeau CG, et al. Thoracoscopic sympathetic clipping for hyperhidrosis: long-term results and reversibility. J Thorac Cardiovasc Surg 2009; 137:1370.
  102. Fibla JJ, Molins L, Mier JM, Vidal G. Effectiveness of sympathetic block by clipping in the treatment of hyperhidrosis and facial blushing. Interact Cardiovasc Thorac Surg 2009; 9:970.
  103. Chang YT, Li HP, Lee JY, et al. Treatment of palmar hyperhidrosis: T(4) level compared with T(3) and T(2). Ann Surg 2007; 246:330.
  104. Cerfolio RJ, De Campos JR, Bryant AS, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg 2011; 91:1642.
  105. Teivelis MP, Wolosker N, Krutman M, et al. Compensatory hyperhidrosis: results of pharmacologic treatment with oxybutynin. Ann Thorac Surg 2014; 98:1797.
  106. Moraites E, Vaughn OA, Hill S. Endoscopic thoracic sympathectomy. Dermatol Clin 2014; 32:541.
  107. Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 2007; 33:S76.
  108. Nestor MS, Park H. Safety and Efficacy of Micro-focused Ultrasound Plus Visualization for the Treatment of Axillary Hyperhidrosis. J Clin Aesthet Dermatol 2014; 7:14.
  109. Garcia J. Treatment of axillary hyperhidrosis/bromidrosis using VASER ultrasound. Aesthetic Plast Surg 2010; 34:120.
  110. Bechara FG, Georgas D, Sand M, et al. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg 2012; 38:736.
  111. Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol 2012; 11:59.
  112. Caplin D, Austin J. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up. J Drugs Dermatol 2014; 13:449.
  113. Goldman A, Wollina U. Subdermal Nd-YAG laser for axillary hyperhidrosis. Dermatol Surg 2008; 34:756.
  114. Pariser DM, Ballard A. Iontophoresis for palmar and plantar hyperhidrosis. Dermatol Clin 2014; 32:491.
  115. Dahl JC, Glent-Madsen L. Treatment of hyperhidrosis manuum by tap water iontophoresis. Acta Derm Venereol 1989; 69:346.
  116. Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol 1987; 123:893.
  117. Levit F. Simple device for treatment of hyperhidrosis by iontophoresis. Arch Dermatol 1968; 98:505.
  118. Hölzle E, Alberti N. Long-term efficacy and side effects of tap water iontophoresis of palmoplantar hyperhidrosis--the usefulness of home therapy. Dermatologica 1987; 175:126.
  119. Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000; 42:1026.
  120. Lowe NJ, Yamauchi PS, Lask GP, et al. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002; 28:822.
  121. Odderson IR. Hyperhidrosis treated by botulinum A exotoxin. Dermatol Surg 1998; 24:1237.
  122. Schnider P, Binder M, Auff E, et al. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997; 136:548.
  123. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998; 38:227.
  124. Baumann L, Slezinger A, Halem M, et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 2005; 31:263.
  125. Campanati A, Giuliodori K, Martina E, et al. Onabotulinumtoxin type A (Botox(®)) versus Incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. J Neural Transm (Vienna) 2014; 121:21.
  126. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003; 149:1041.
  127. Benohanian A. Treatment of recalcitrant plantar hyperhidrosis with type-A botulinum toxin injections and aluminum chloride in salicylic acid gel. Dermatol Online J 2008; 14:5.
  128. Vlahovic TC, Dunn SP, Blau JC, Gauthier C. Injectable botulinum toxin as a treatment for plantar hyperhidrosis: a case study. J Am Podiatr Med Assoc 2008; 98:156.
  129. Campanati A, Bernardini ML, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol 2007; 17:52.
  130. Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 2004; 43:969.
  131. Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin 2014; 32:505.
  132. Lecouflet M, Leux C, Fenot M, et al. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: a study of 28 patients. J Am Acad Dermatol 2014; 70:1083.
  133. Rieger R, Pedevilla S, Pöchlauer S. Endoscopic lumbar sympathectomy for plantar hyperhidrosis. Br J Surg 2009; 96:1422.
  134. Neumayer C, Panhofer P, Zacherl J, Bischof G. Effect of endoscopic thoracic sympathetic block on plantar hyperhidrosis. Arch Surg 2005; 140:676.
  135. George SM, Atkinson LR, Farrant PB, Shergill BS. Botulinum toxin for focal hyperhidrosis of the face. Br J Dermatol 2014; 170:211.
  136. Teive HA, Troiano AR, Robert F, et al. Botulinum toxin for treatment of Frey's syndrome: report of two cases. Arq Neuropsiquiatr 2003; 61:256.
  137. Bjerkhoel A, Trobbe O. Frey's syndrome: treatment with botulinum toxin. J Laryngol Otol 1997; 111:839.
  138. Restivo DA, Lanza S, Patti F, et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology 2002; 59:1971.
  139. Böger A, Herath H, Rompel R, Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol 2000; 247:857.
  140. Glaser DA, Galperin TA. Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles. Dermatol Clin 2014; 32:517.
  141. Kim WO, Kil HK, Yoon KB, Yoon DM. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 2008; 158:1094.
  142. Hyun MY, Son IP, Lee Y, et al. Efficacy and safety of topical glycopyrrolate in patients with facial hyperhidrosis: a randomized, multicentre, double-blinded, placebo-controlled, split-face study. J Eur Acad Dermatol Venereol 2015; 29:278.
  143. Cladellas E, Callejas MA, Grimalt R. A medical alternative to the treatment of compensatory sweating. Dermatol Ther 2008; 21:406.
  144. Mackenzie A, Burns C, Kavanagh G. Topical glycopyrrolate for axillary hyperhidrosis. Br J Dermatol 2013; 169:483.